HealthEquity's Net Income Soars 67% on Strong Custodial Revenue Growth

TL;DR

**HealthEquity is crushing it, with net income up 67% and smart share buybacks, making HQY a solid buy.**

AI Summary

HealthEquity, Inc. reported a significant increase in net income for the three and six months ended July 31, 2025. Net income for the three months rose to $59.85 million, a 67.1% increase from $35.82 million in the prior year. For the six months, net income reached $113.77 million, up 76.0% from $64.64 million in the same period last year. Total revenue increased by 8.6% to $325.84 million for the three months and by 11.8% to $656.68 million for the six months, driven primarily by a 15.3% increase in custodial revenue to $159.88 million for the quarter. Operating expenses decreased slightly by 1.5% to $142.98 million for the three months, largely due to lower general and administrative expenses, which fell by 7.0% to $29.99 million. The company also made principal payments on long-term debt totaling $50.00 million and repurchased $125.81 million of common stock during the six months ended July 31, 2025, demonstrating active capital management. Cash and cash equivalents increased to $304.46 million from $295.95 million at January 31, 2025.

Why It Matters

This strong financial performance, particularly the significant jump in net income and custodial revenue, signals robust health in HealthEquity's core business of administering HSAs and CDBs. For investors, this indicates efficient operations and effective capital deployment, including substantial share repurchases of $125.81 million. Employees benefit from a stable and growing company, while customers can expect continued investment in services. In a competitive landscape, HealthEquity's ability to grow revenue and control costs, as evidenced by a 1.5% decrease in operating expenses, positions it favorably against peers in the consumer-directed healthcare benefits sector.

Risk Assessment

Risk Level: low — The company's financial health appears strong, with net income significantly increasing by 67.1% for the three months and 76.0% for the six months ended July 31, 2025. Furthermore, cash and cash equivalents increased to $304.46 million, and total current assets of $492.83 million comfortably exceed total current liabilities of $116.58 million, indicating strong liquidity.

Analyst Insight

Investors should consider increasing their position in HQY, given the substantial net income growth of 67.1% and 76.0% for the three and six months, respectively, and the company's proactive capital management through $125.81 million in share repurchases. The strong custodial revenue growth of 15.3% suggests a healthy core business, making it an attractive long-term hold.

Financial Highlights

debt To Equity

0.59

revenue

$325.84M

operating Margin

71.4%

total Assets

$3,416.68M

total Debt

$1,006.83M

net Income

$59.85M

eps

$0.68

gross Margin

71.4%

cash Position

$304.46M

revenue Growth

+8.6%

Revenue Breakdown

Key Numbers

• $59.85M — Net Income (3 months) (Increased 67.1% from $35.82M year-over-year)
• $113.77M — Net Income (6 months) (Increased 76.0% from $64.64M year-over-year)
• $325.84M — Total Revenue (3 months) (Increased 8.6% from $299.93M year-over-year)
• $656.68M — Total Revenue (6 months) (Increased 11.8% from $587.53M year-over-year)
• $159.88M — Custodial Revenue (3 months) (Increased 15.3% from $138.68M year-over-year)
• $142.98M — Total Operating Expenses (3 months) (Decreased 1.5% from $145.12M year-over-year)
• $125.81M — Common Stock Repurchases (6 months) (Significant capital return to shareholders)
• $304.46M — Cash and Cash Equivalents (Increased from $295.95M at January 31, 2025)
• $0.68 — Diluted EPS (3 months) (Increased from $0.40 year-over-year)
• $1.29 — Diluted EPS (6 months) (Increased from $0.73 year-over-year)

Key Players & Entities

• HEALTHEQUITY, INC. (company) — registrant
• Bloomberg (company) — publisher
• SEC (regulator) — filing authority
• $59.85 million (dollar_amount) — net income for three months ended July 31, 2025
• $35.82 million (dollar_amount) — net income for three months ended July 31, 2024
• $113.77 million (dollar_amount) — net income for six months ended July 31, 2025
• $64.64 million (dollar_amount) — net income for six months ended July 31, 2024
• $325.84 million (dollar_amount) — total revenue for three months ended July 31, 2025
• $159.88 million (dollar_amount) — custodial revenue for three months ended July 31, 2025
• $125.81 million (dollar_amount) — repurchases of common stock for six months ended July 31, 2025

FAQ

Industry Context

HealthEquity operates in the rapidly growing consumer-directed healthcare market, administering HSAs and other benefits. The industry is characterized by increasing adoption of these accounts by employers and employees seeking tax advantages for healthcare spending. Competition exists from other HSA administrators and financial institutions offering similar services.

Regulatory Implications

As a financial services provider in the healthcare sector, HealthEquity is subject to various regulations, including those related to data privacy (e.g., HIPAA) and financial compliance. Changes in healthcare legislation or tax laws could impact the utilization and administration of HSAs and CDBs.

What Investors Should Do

1. Monitor custodial revenue growth
2. Analyze operating expense trends
3. Evaluate capital allocation strategy
4. Assess impact of potential regulatory changes

Key Dates

• 2025-07-31: End of the second quarter for fiscal year 2025 — Reporting period for the presented financial results, showing strong net income and revenue growth.
• 2025-01-31: End of the first quarter for fiscal year 2025 — Balance sheet date, showing a slight increase in cash and cash equivalents from this point.

Glossary

Health Savings Accounts (HSAs)

Tax-advantaged savings accounts for medical expenses. (Core product administered by HealthEquity, driving custodial revenue.)

Consumer-Directed Benefits (CDBs)

A category of benefits that give consumers more control, including HSAs, HRAs, and FSAs. (Complementary offerings to HSAs, contributing to the company's service offerings.)

Custodial Revenue

Revenue generated from holding and managing client funds in HSAs and other accounts. (A primary revenue stream for HealthEquity, showing significant growth.)

Interchange Revenue

Revenue earned from transaction fees, often associated with debit card usage for health accounts. (Another significant revenue component, demonstrating growth in account activity.)

Diluted EPS

Earnings per share calculated after accounting for all dilutive potential common shares. (Key profitability metric for shareholders, showing substantial year-over-year improvement.)

Year-Over-Year Comparison

Compared to the prior year's filing period, HealthEquity has demonstrated robust financial performance. Total revenue for the three months ended July 31, 2025, increased by 8.6% to $325.84 million, and net income saw a substantial surge of 67.1% to $59.85 million. Operating expenses saw a slight decrease of 1.5%, primarily due to lower general and administrative costs. This indicates improved operational efficiency alongside revenue growth. No new significant risk factors were highlighted in the provided excerpt compared to the general understanding of the industry.

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share HQY The NASDAQ Global Select

Filing Documents

• hqy-20250731.htm (10-Q) — 999KB
• exhibit311-ceo302xfy26q2.htm (EX-31.1) — 11KB
• exhibit312-cfo302xfy26q2.htm (EX-31.2) — 11KB
• exhibit321-ceo906xfy26q2.htm (EX-32.1) — 6KB
• exhibit322-cfo906xfy26q2.htm (EX-32.2) — 6KB
• 0001428336-25-000029.txt ( ) — 5385KB
• hqy-20250731.xsd (EX-101.SCH) — 36KB
• hqy-20250731_cal.xml (EX-101.CAL) — 56KB
• hqy-20250731_def.xml (EX-101.DEF) — 151KB
• hqy-20250731_lab.xml (EX-101.LAB) — 532KB
• hqy-20250731_pre.xml (EX-101.PRE) — 355KB
• hqy-20250731_htm.xml (XML) — 596KB

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION

Financial statements

Item 1. Financial statements Condensed consolidated balance sheets as of July 31, 2025 (unaudited) and January 31, 2025 3 Condensed consolidated statements of operations for the three and six months ended July 31, 2025 and 2024 (unaudited) 4 Condensed consolidated statements of comprehensive income for the three and six months ended July 31, 2025 and 2024 (unaudited) 5 Condensed consolidated statements of stockholders' equity for the three and six months ended July 31, 2025 and 2024 (unaudited) 6 Condensed consolidated statements of cash flows for the six months ended July 3 1 , 2025 and 2024 (unaudited) 7 Notes to condensed consolidated financial statements (unaudited) 9

Management's discussion and analysis of financial condition and results of operations

Item 2. Management's discussion and analysis of financial condition and results of operations 19

Quantitative and qualitative disclosures about market risk

Item 3. Quantitative and qualitative disclosures about market risk 35

Controls and procedures

Item 4. Controls and procedures 36

OTHER INFORMATION

Part II. OTHER INFORMATION

Legal proceedings

Item 1. Legal proceedings 37

Risk factors

Item 1A. Risk factors 37

Other information

Item 5. Other information 38

Exhibits

Item 6. Exhibits 39

Signatures

Signatures 40 -2-

Financial information

Part I. Financial information

Financial statements

Item 1. Financial statements HealthEquity, Inc. and subsidiaries Condensed consolidated balance sheets (in thousands, except par value) July 31, 2025 January 31, 2025 (unaudited) Assets Current assets Cash and cash equivalents $ 304,461 $ 295,948 Accounts receivable, net of allowance for doubtful accounts of $ 920 and $ 2,070 as of July 31, 2025 and January 31, 2025, respectively 111,164 118,006 Prepaid expenses and other current assets 77,207 63,795 Total current assets 492,832 477,749 Property and equipment, net 3,088 3,239 Operating lease right-of-use assets 39,756 43,185 Intangible assets, net 1,152,456 1,204,658 Goodwill 1,648,145 1,648,145 Other assets 80,401 71,574 Total assets $ 3,416,678 $ 3,448,550 Liabilities and stockholders' equity Current liabilities Accounts payable $ 9,600 $ 14,361 Accrued compensation 32,482 69,330 Accrued liabilities 64,543 62,631 Operating lease liabilities 9,950 10,001 Total current liabilities 116,575 156,323 Long-term liabilities Long-term debt, net of issuance costs 1,006,834 1,056,301 Operating lease liabilities, non-current 38,240 42,219 Other long-term liabilities 21,993 22,962 Deferred tax liability 86,615 55,834 Total long-term liabilities 1,153,682 1,177,316 Total liabilities 1,270,257 1,333,639 Commitments and contingencies (see Note 5) Stockholders' equity Preferred stock, $ 0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2025 and January 31, 2025, respectively — — Common stock, $ 0.0001 par value, 900,000 shares authorized, 86,421 and 86,536 shares issued and outstanding as of July 31, 2025 and January 31, 2025, respectively 9 9 Additional paid-in capital 1,919,312 1,905,628 Accumulated other comprehensive income 203 — Accumulated earnings 226,897 209,274 Total stockholders' equity 2,146,421 2,114,911 Total liabilities and stockholders' equity $ 3,416,678 $ 3,448,550 See accompanying notes to condensed consolidated financial stat

Business

Business HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts ("HSAs") and complementary consumer-directed benefits ("CDBs"), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers. Principles of consolidation The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Segments The Company is managed as a single operating segment that provides administration services in connection with HSAs and other CDBs, which reflects the way in which its chief operating decision maker ("CODM"), the Chief Executive Officer, reviews the Company's financial performance and makes decisions about resource allocation. The CODM assesses the performance of the Company, monitors actual financial results against budgets, and makes resource allocation decisions with a focus on the Company's consolidated results as presented in the condensed consolidated statements of operations. The Company's measure of profitability is net income. Single segment-level financial information, including total assets, significant non-cash transactions, and capital expenditures, is contained in the accompanying condensed consolidated financial statements and related notes. The Company does not generate material international revenues. All long-lived assets are maintained in the United States of America. Basis of presentation The accompanying condensed consolidated financial statements as of July 31, 2025 and for the three and six months ended July 31, 2025 and 2024 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and t

View Full Filing

View this 10-Q filing on SEC EDGAR